Eton Pharmaceuticals, Inc. Stock Issued During Period, Shares, Employee Stock Purchase Plans
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Eton Pharmaceuticals, Inc. stock issued during period, shares, employee stock purchase plans for the quarter ending 2023-12-31 was 29.17K shares.
- Eton Pharmaceuticals, Inc. stock issued during period, shares, employee stock purchase plans for the quarter ending 2023-09-30 was 0.00 shares.
- Eton Pharmaceuticals, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2025 was 16.89K shares, a 79.13% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2024 was 80.93K shares, a 6.74% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2023 was 86.78K shares, a 24.18% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2022 was 69.88K shares.
| Period end | Stock Issued During Period, Shares, Employee Stock Purchase Plans 3 month | Stock Issued During Period, Shares, Employee Stock Purchase Plans 12 month |
|---|---|---|
| 2025-12-31 | 16.89K shares 10-K · filed 2026-03-19 | |
| 2024-12-31 | 80.93K shares 10-K · filed 2026-03-19 | |
| 2023-12-31 | 29.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 86.78K shares 10-K · filed 2026-03-19 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-12-31 | 69.88K shares 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |